-

Valerio Therapeutics: Postponement of 2024 Annual Financial Report Publication and the Approval of Financial Statements

PARIS--(BUSINESS WIRE)--Regulatory News:

Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO) (the “Company”) announces the postponement of the publication of its 2024 annual financial report, initially scheduled for April 30, 2025, as well as the finalization and approval of its statutory and consolidated financial statements for 2024.

The Company is facing significant difficulties in accessing the accounting records of its U.S. subsidiary, Valerio Therapeutics Inc. Although the assets related to this subsidiary have been impaired in the Company's statutory accounts and the subsidiary ceased all activities at the end of 2024, this delay in the accounting treatment of Valerio Therapeutics Inc. currently prevents the Company from finalizing its statutory and, consequently, its consolidated financial statements. In 2024, the re-invoicing to the Company of costs from Valerio Therapeutics Inc. (including employee and R&D expenses) remained substantial and therefore has a significant impact on the Company's annual accounts.

As a result, the finalization of the Company’s 2024 statutory and consolidated financial statements and the publication of the 2024 annual financial report will not occur before the end of July 2025. The approval of the 2024 annual financial statements will take place in September 2025.

The Company's cash position remains low. The Company's main shareholder intends to provide funding for Valerio Therapeutics' ongoing operations through June 2025. In the meantime, the Company is continuing discussions with its stakeholders and is seeking to reach an agreement necessary to secure its financial and cash position through the end of 2025.

For more information, visit www.valeriotx.com.

VALERIO THERAPEUTICS
49 boulevard du Général Martial Valin
75015 Paris70.38.33.99

Société Anonyme à Conseil d’Administration au capital de 21 610 998,20 euros
Siège social: 49 boulevard du Général Martial Valin, 75015 Paris

Contacts

Valerio Therapeutics
Relations avec les investisseurs :
ir@valeriotx.com | +33 (0) 1 70 38 33 99 »

Valerio Therapeutics S.A.

BOURSE:ALVIO
Release Versions
EnglishFrench

Contacts

Valerio Therapeutics
Relations avec les investisseurs :
ir@valeriotx.com | +33 (0) 1 70 38 33 99 »

More News From Valerio Therapeutics S.A.

Valerio Therapeutics Provides an Update on Its Business and Presents Its Financial Results for the First Half of 2026

VILLEJUIF, France--(BUSINESS WIRE)--Regulatory News: Valerio Therapeutics (FR0010095596 - ALVIO), a pioneering biotechnology company in the field of next-generation precision therapies (“Valerio”, or the “Company”), provides an update on its operations and presents its financial results for the half-year ended 30 June 2026. “The first half of 2026 marked a decisive milestone in the consolidation of our strategic refocusing and in the transformation of Valerio Therapeutics. The operational launc...

Valerio Therapeutics Announces Signing of Definitive Agreements for the Acquisition of Etherna Immunotherapies, Building a Leading Platform in Targeted RNA, and €40.25 Million PIPE Financing From New and Existing Investors 

VILLEJUIF, France--(BUSINESS WIRE)--Regulatory News: Valerio Therapeutics (FR0010095596 - ALVIO), a biotechnology company pioneering next-generation precision-guided RNA therapeutics ("Valerio" or the "Company"), today announces the signing of a definitive share purchase agreement (the "SPA") and of the related contribution agreement (the "Contribution Agreement") for the acquisition of 100% of the share capital and voting rights of Etherna Immunotherapies NV ("Etherna") (the "Acquisition"), ba...

Valerio Therapeutics and Etherna Immunotherapies Progress Towards Finalisation of Transaction Documentation Regarding the Contemplated Acquisition

VILLEJUIF, France--(BUSINESS WIRE)--Regulatory News: Valerio Therapeutics (FR0010095596 - ALVIO), a biotechnology company pioneering next-generation precision-guided RNA therapeutics ("Valerio" or the "Company"), provides an update on the contemplated acquisition of 100% of the share capital of Etherna Immunotherapies NV ("Etherna") (the "Acquisition"). On July 1, 2026, Valerio announced the submission of a binding offer for the Acquisition on the basis of an enterprise value of EUR 30 million....
Back to Newsroom